EMBECTA CORP. Gross Profit
EMBECTA CORP. (EMBC) reported Gross Profit of $153.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement
us-gaap:GrossProfit · last filed 2026-08-07
- EMBECTA CORP. gross profit for the quarter ending 2026-06-30 was $153.30M, a 22.22% decline year-over-year.
- EMBECTA CORP. gross profit for the quarter ending 2026-03-31 was $127.80M, a 22.12% decline year-over-year.
- EMBECTA CORP. gross profit for the quarter ending 2025-12-31 was $161.70M, a 2.93% increase year-over-year.
- EMBECTA CORP. gross profit for the quarter ending 2025-09-30 was $158.50M, a 8.80% decline year-over-year.
- EMBECTA CORP. gross profit for fiscal 2025 was $676.80M, a 7.94% decline from fiscal 2024.
- EMBECTA CORP. gross profit for fiscal 2024 was $735.20M, a 1.96% decline from fiscal 2023.
- EMBECTA CORP. gross profit for fiscal 2023 was $749.90M, a 3.23% decline from fiscal 2022.
- EMBECTA CORP. gross profit for fiscal 2022 was $774.90M, a 3.19% decline from fiscal 2021.
| Period end | Gross Profit 3 month | Gross Profit 6 month | Gross Profit 9 month | Gross Profit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $153.30M 10-Q · filed 2026-08-07 | $281.10M derived: sum of 2 quarters · filed 2026-08-07 | $442.80M 10-Q · filed 2026-08-07 | $601.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $127.80M 10-Q · filed 2026-05-05 | $289.50M 10-Q · filed 2026-05-05 | $448.00M derived: sum of 3 quarters · filed 2026-05-05 | $645.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $161.70M 10-Q · filed 2026-02-05 | $320.20M derived: sum of 2 quarters · filed 2026-02-05 | $517.30M derived: sum of 3 quarters · filed 2026-08-07 | $681.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $158.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $355.60M derived: sum of 2 quarters · filed 2026-08-07 | $519.70M derived: sum of 3 quarters · filed 2026-08-07 | $676.80M 10-K · filed 2025-11-25 |
| 2025-06-30 | $197.10M 10-Q · filed 2026-08-07 | $361.20M derived: sum of 2 quarters · filed 2026-08-07 | $518.30M 10-Q · filed 2026-08-07 | $692.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $164.10M 10-Q · filed 2026-05-05 | $321.20M 10-Q · filed 2026-05-05 | $495.00M derived: sum of 3 quarters · filed 2026-05-05 | $685.10M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $157.10M 10-Q · filed 2026-02-05 | $330.90M derived: sum of 2 quarters · filed 2026-02-05 | $521.00M derived: sum of 3 quarters · filed 2026-02-05 | $706.40M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $173.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $363.90M derived: sum of 2 quarters · filed 2025-11-25 | $549.30M derived: sum of 3 quarters · filed 2025-11-25 | $735.20M 10-K · filed 2025-11-25 |
| 2024-06-30 | $190.10M 10-Q · filed 2025-08-08 | $375.50M derived: sum of 2 quarters · filed 2025-08-08 | $561.40M 10-Q · filed 2025-08-08 | $743.20M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $185.40M 10-Q · filed 2025-05-09 | $371.30M 10-Q · filed 2025-05-09 | $553.10M derived: sum of 3 quarters · filed 2025-11-25 | $742.60M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $185.90M 10-Q · filed 2025-02-06 | $367.70M derived: sum of 2 quarters · filed 2025-11-25 | $557.20M derived: sum of 3 quarters · filed 2025-11-25 | $747.00M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $181.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $371.30M derived: sum of 2 quarters · filed 2025-11-25 | $561.10M derived: sum of 3 quarters · filed 2025-11-25 | $749.90M 10-K · filed 2025-11-25 |
| 2023-06-30 | $189.50M 10-Q · filed 2024-08-09 | $379.30M derived: sum of 2 quarters · filed 2024-08-09 | $568.10M 10-Q · filed 2024-08-09 | $745.00M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | $189.80M 10-Q · filed 2024-05-09 | $378.60M 10-Q · filed 2024-05-09 | $555.50M derived: sum of 3 quarters · filed 2024-12-11 | $758.40M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $188.80M 10-Q · filed 2024-02-09 | $365.70M derived: sum of 2 quarters · filed 2024-12-11 | $568.60M derived: sum of 3 quarters · filed 2024-12-11 | $759.80M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $176.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $379.80M derived: sum of 2 quarters · filed 2024-12-11 | $571.00M derived: sum of 3 quarters · filed 2024-12-11 | $774.90M 10-K · filed 2024-12-11 |
| 2022-06-30 | $202.90M 10-Q · filed 2023-08-08 | $394.10M derived: sum of 2 quarters · filed 2023-08-08 | $598.00M 10-Q · filed 2023-08-08 | $808.20M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $191.20M 10-Q · filed 2023-05-12 | $395.10M 10-Q · filed 2023-05-12 | $605.30M derived: sum of 3 quarters · filed 2023-11-29 | $807.90M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $203.90M 10-Q · filed 2023-02-14 | $414.10M derived: sum of 2 quarters · filed 2023-11-29 | $616.70M derived: sum of 3 quarters · filed 2023-11-29 | $813.00M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $210.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $412.80M derived: sum of 2 quarters · filed 2023-11-29 | $609.10M derived: sum of 3 quarters · filed 2023-11-29 | $800.40M 10-K · filed 2023-11-29 |
| 2021-06-30 | $202.60M 10-Q · filed 2022-08-15 | $398.90M derived: sum of 2 quarters · filed 2022-08-15 | $590.20M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $196.30M 10-Q · filed 2022-05-13 | $387.60M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $191.30M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $762.60M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |